Literature DB >> 20332329

Differences between orofacial inflammation and cancer pain.

N Harano1, K Ono, K Hidaka, A Kai, O Nakanishi, K Inenaga.   

Abstract

Rat models of orofacial cancer exhibit both allodynia and hyperalgesia; however, it is unclear whether cancer-induced pain is secondary to cancer-induced inflammation. To address this question, we compared the effects of an anti-inflammatory drug, indomethacin, on pain and neurochemical changes in the medullary dorsal horn in orofacial inflammation and cancer models. Daily peripheral administration of indomethacin largely suppressed mechanical allodynia and thermal hyperalgesia in the inflammation model. The same procedure suppressed allodynia and hyperalgesia in the cancer model, but the suppression was weak when compared with that in the inflammation model. In the medullary dorsal horn, calcitonin gene-related peptide and substance P levels were significantly increased in the inflammation model, but did not change in the cancer model. These results suggest that pain in the orofacial cancer model is not significantly mediated by cancer-induced peripheral inflammation, although it may have some involvement.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20332329     DOI: 10.1177/0022034510363095

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  8 in total

Review 1.  Biologic mechanisms of oral cancer pain and implications for clinical therapy.

Authors:  C T Viet; B L Schmidt
Journal:  J Dent Res       Date:  2011-10-04       Impact factor: 6.116

Review 2.  The Neurobiology of Cancer Pain.

Authors:  Brian L Schmidt
Journal:  J Oral Maxillofac Surg       Date:  2015-12       Impact factor: 1.895

Review 3.  The neurobiology of cancer pain.

Authors:  Brian L Schmidt
Journal:  Neuroscientist       Date:  2014-03-24       Impact factor: 7.519

4.  Behavioral testing in rodent models of orofacial neuropathic and inflammatory pain.

Authors:  Agnieszka Krzyzanowska; Carlos Avendaño
Journal:  Brain Behav       Date:  2012-08-15       Impact factor: 2.708

Review 5.  Nanotechnology-based drug delivery systems for treatment of oral cancer: a review.

Authors:  Giovana Calixto; Jéssica Bernegossi; Bruno Fonseca-Santos; Marlus Chorilli
Journal:  Int J Nanomedicine       Date:  2014-08-08

6.  The impact of tumor immunogenicity on cancer pain phenotype using syngeneic oral cancer mouse models.

Authors:  Nicole L Horan; Lisa A McIlvried; Megan A Atherton; Mona M Yuan; John C Dolan; Nicole N Scheff
Journal:  Front Pain Res (Lausanne)       Date:  2022-09-12

7.  Tumor necrosis factor alpha secreted from oral squamous cell carcinoma contributes to cancer pain and associated inflammation.

Authors:  Nicole N Scheff; Yi Ye; Aditi Bhattacharya; Justin MacRae; Dustin N Hickman; Atul K Sharma; John C Dolan; Brian L Schmidt
Journal:  Pain       Date:  2017-12       Impact factor: 7.926

8.  Prostanoid-dependent spontaneous pain and PAR2-dependent mechanical allodynia following oral mucosal trauma: involvement of TRPV1, TRPA1 and TRPV4.

Authors:  Misa Ito; Kentaro Ono; Suzuro Hitomi; Tomotaka Nodai; Teppei Sago; Kiichiro Yamaguchi; Nozomu Harano; Kaori Gunnjigake; Ryuji Hosokawa; Tatsuo Kawamoto; Kiyotoshi Inenaga
Journal:  Mol Pain       Date:  2017-01       Impact factor: 3.395

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.